|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2010-6-18
|
|
pubmed:abstractText |
The efficacy and safety of cyclophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -tositumomab therapy were evaluated in a multicenter phase II study in patients with untreated low-grade follicular lymphoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3035-41
|
|
pubmed:meshHeading |
pubmed-meshheading:20458031-Adult,
pubmed-meshheading:20458031-Aged,
pubmed-meshheading:20458031-Antibodies, Monoclonal,
pubmed-meshheading:20458031-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20458031-Combined Modality Therapy,
pubmed-meshheading:20458031-Cyclophosphamide,
pubmed-meshheading:20458031-Feasibility Studies,
pubmed-meshheading:20458031-Follow-Up Studies,
pubmed-meshheading:20458031-Humans,
pubmed-meshheading:20458031-Lymphoma, Follicular,
pubmed-meshheading:20458031-Lymphoma, Non-Hodgkin,
pubmed-meshheading:20458031-Maximum Tolerated Dose,
pubmed-meshheading:20458031-Middle Aged,
pubmed-meshheading:20458031-Prednisone,
pubmed-meshheading:20458031-Radioimmunotherapy,
pubmed-meshheading:20458031-Remission Induction,
pubmed-meshheading:20458031-Survival Rate,
pubmed-meshheading:20458031-Time Factors,
pubmed-meshheading:20458031-Treatment Outcome,
pubmed-meshheading:20458031-Vincristine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
|
|
pubmed:affiliation |
University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
